Dow Up0.09% Nasdaq Up0.25%

BioTime, Inc. (BTX)

-NYSE MKT
3.35 Down 0.01(0.30%) 9:50AM EDT - Nasdaq Real Time Price
ProfileGet Profile for:
BioTime, Inc.
1301 Harbor Bay Parkway
Alameda, CA 94502
United States - Map
Phone: 510-521-3390
Fax: 510-521-3389
Website: http://www.biotimeinc.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:106

Business Summary 

BioTime, Inc., a biotechnology company, is engaged in the research and product development in the field of regenerative medicine. The company primarily focuses on regenerative medicine, which refers to therapies based on human embryonic stem cell and induced pluripotent stem cell technology designed to rebuild cell and tissue function lost due to degenerative disease or injury. It develops and markets research products in the field of stem cells, including an array of proprietary PureStem cell lines and associated ESpan culture media, cGMP-capable human embryonic stem cell lines, and differentiation kits, as well as offers Hextend, a blood plasma volume expander to treat hypovolemia in surgery, emergency trauma treatment, and other applications. The company is developing Renevia, a biocompatible, implantable hyaluronan, and collagen-based matrix for cell delivery in human clinical applications; and stem cell-based therapies for retinal and neurological disorders. It also develops HyStem hydrogels, such as ReGlyde, a cross-linked thiol-modified hyaluronan hydrogel to manage and protect tendon injuries; and Premvia, a hydrogel formulation to manage wounds, as well as PanC-Dx, a non-invasive cancer products for use in detecting breast, bladder, and lung cancers. In addition, the company markets GeneCards, a human gene database. Further, it is developing an integrated database suite to complement GeneCards that would include the LifeMap database of embryonic development, stem cell research, and regenerative medicine, as well as MalaCards, the human disease database. Additionally, the company develops cell based therapeutic products for diseases, such as neurological disorders, age related macular degeneration, orthopedic disorders, and cardiovascular disease and related ischemic disorders. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on BioTime, Inc.

Corporate Governance 
BioTime, Inc.’s ISS Governance QuickScore as of Oct 1, 2014 is 7. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 5; Compensation: 8.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Dr. Michael D. West Ph.D., 61
Chief Exec. Officer, Pres and Director
783.00K0.00
Mr. Robert W. Peabody CPA, 60
Chief Financial Officer, Chief Operating Officer, Principal Accounting Officer and Sr. VP
562.00K0.00
Dr. Lesley A. Stolz Ph.D., 50
Exec. VP of Corp. Devel.
104.00K0.00
Mr. William P. Tew Ph.D., 68
Chief Commercial Officer
327.00K0.00
Mr. Rafhael Cedeno ,
Chief Technology Officer and Head of Product
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders